WallStreetZenWallStreetZen

NASDAQ: GOSS
Gossamer Bio Inc Stock

$2.78-0.14 (-4.79%)
Updated Feb 3, 2023
GOSS Price
$2.78
Fair Value Price
$4.46
Market Cap
$262.65M
52 Week Low
$1.57
52 Week High
$15.20
P/E
-0.96x
P/B
4.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$229.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.74
Operating Cash Flow
-$180M
Beta
1.04
Next Earnings
Mar 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A

GOSS Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GOSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GOSS ($2.78) is undervalued by 37.71% relative to our estimate of its Fair Value price of $4.46 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GOSS ($2.78) is significantly undervalued by 37.71% relative to our estimate of its Fair Value price of $4.46 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GOSS due diligence checks available for Premium users.

Be the first to know about important GOSS news, forecast changes, insider trades & much more!

GOSS News

Valuation

GOSS fair value

Fair Value of GOSS stock based on Discounted Cash Flow (DCF)
Price
$2.78
Fair Value
$4.46
Undervalued by
37.71%
GOSS ($2.78) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GOSS ($2.78) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GOSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GOSS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.96x
Industry
10.7x
Market
15.09x

GOSS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.66x
Industry
5.11x
GOSS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GOSS's financial health

Profit margin

Revenue
$0.0
Net Income
-$59.4M
Profit Margin
0%
GOSS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$323.5M
Liabilities
$267.2M
Debt to equity
4.74
GOSS's short-term assets ($312.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOSS's short-term assets ($312.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$37.0M
Investing
-$22.6M
Financing
$119.2M
GOSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GOSS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GOSS$262.65M-4.79%-0.96x4.66x
FENC$262.64M-1.38%-12.36x93.73x
GLSI$262.49M-1.79%-35.84x17.03x
OTLK$262.44M-3.36%-3.71x30.04x
DBVT$263.27M-3.45%-2.59x1.24x

Gossamer Bio Stock FAQ

What is Gossamer Bio's quote symbol?

NASDAQ: GOSS) Gossamer Bio trades on the NASDAQ under the ticker symbol GOSS. Gossamer Bio stock quotes can also be displayed as NASDAQ: GOSS.

If you're new to stock investing, here's how to buy Gossamer Bio stock.

What is the 52 week high and low for Gossamer Bio (NASDAQ: GOSS)?

(NASDAQ: GOSS) Gossamer Bio's 52-week high was $15.20, and its 52-week low was $1.57. It is currently -81.7% from its 52-week high and 77.07% from its 52-week low.

How much is Gossamer Bio stock worth today?

(NASDAQ: GOSS) Gossamer Bio currently has 94,476,801 outstanding shares. With Gossamer Bio stock trading at $2.78 per share, the total value of Gossamer Bio stock (market capitalization) is $262.65M.

Gossamer Bio stock was originally listed at a price of $17.94 in Feb 8, 2019. If you had invested in Gossamer Bio stock at $17.94, your return over the last 3 years would have been -84.5%, for an annualized return of -46.29% (not including any dividends or dividend reinvestments).

How much is Gossamer Bio's stock price per share?

(NASDAQ: GOSS) Gossamer Bio stock price per share is $2.78 today (as of Feb 3, 2023).

What is Gossamer Bio's Market Cap?

(NASDAQ: GOSS) Gossamer Bio's market cap is $262.65M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gossamer Bio's market cap is calculated by multiplying GOSS's current stock price of $2.78 by GOSS's total outstanding shares of 94,476,801.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.